Exploring targeted therapy in retinal vasculopathy with cerebral leukoencephalopathy: a case report and review of literature
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a rare autosomal dominant microvascular disorder caused by C-terminal truncating mutations in TREX1 gene, which impair protein localization and lead to multisystem involvement. We report a patient carrying the pathogenic TREX1 variant NM_033629.6:c.703dup (p.Val235fs), the most frequently described mutation in RVCL-S, whose clinical course was consistent with the classic phenotype but with simultaneous pulmonary granulomatous lesions compatible with sarcoidosis. Transcriptomic analysis in both the patient and his pre-asymptomatic daughter, who carries the same variant, revealed a similarly mild upregulation of inflammatory signaling pathways. Treatment with a Janus kinase inhibitor in the patient was followed by transient clinical stabilization before subsequent progression. This case expands the phenotypic spectrum of RVCL-S and underscores the importance of systematic immunological monitoring and clinical surveillance to support future development of timely strategies in asymptomatic carriers.
Authors
- Paloma Sánchez‐Mateos (ORCID: https://orcid.org/0000-0001-6589-4445)
- Elena García-Martínez
- M. Barrientos Guerrero
- Héctor Balastegui Martín
- Patricia Tato-Moreno
- Anna Mensa-Vilaro
- Cristina Lavilla Olleros
- María Esther Durán-García
Institutions
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital Clínic de Barcelona (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1707532
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00